# A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

> **NCT07324616** · PHASE1 · RECRUITING · sponsor: **Edgewise Therapeutics, Inc.** · enrollment: 32 (estimated)

## Conditions studied

- Hepatic Impairment (HI)

## Interventions

- **DRUG:** EDG-7500

## Key facts

- **NCT ID:** NCT07324616
- **Lead sponsor:** Edgewise Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-26
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07324616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07324616, "A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07324616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*